Skip Navigation


JAC Advance Access originally published online on December 12, 2002
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
51/1/196    most recent
dkg030v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Jones, M. E.
Right arrow Articles by Sahm, D. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jones, M. E.
Right arrow Articles by Sahm, D. F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2003) 51, 196-199
© 2003 The British Society for Antimicrobial Chemotherapy

Correspondence

Activity of faropenem, a new furanem, against European respiratory pathogens collected during 2000–2001: a comparison with other ß-lactam agents

Mark E. Jones1,*, Renée S. Blosser-Middleton2, Ian A. Critchley2, James A. Karlowsky2, Clyde Thornsberry3 and Daniel F. Sahm2

Focus Technologies, Inc., 1 Koninginneweg 11, Hilversum 1217 KP, The Netherlands; 2 Herndon, VA; 3 Franklin, TN, USA

The first 10% of the full text of this article appears below.

Sir,

Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis comprise the most common causative agents of respiratory tract infections (RTIs). Resistance to penicillin and other ß-lactam agents commonly used as empirical therapies to treat RTIs is an established concern. This has prompted the development of new oral agents that can be used to treat RTIs in both adult and paediatric patients. Faropenem, an investigational compound, the first in the furanem class of compounds intended for oral administration and sharing structural similarities with ß-lactams, has been shown to exhibit broad-spectrum . . . [Full Text of this Article]

Acknowledgements


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?